ArticleJournal of anesthesia2017
Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery.
Article in Journal of anesthesia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01864187 (A Study of the Pharmacokinetics of Dexmedetomidine in Morbid Obesity.), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study of the Pharmacokinetics of Dexmedetomidine in Morbid Obesity.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Dexmedetomidine Dosing Strategies in Sedation and Anesthesia: Pharmacokinetics, Safety, and Clinical Applications - A Narrative Review.Drug design, development and therapy · 2026Review
- A Multidisciplinary Approach to Obesity Hypoventilation Syndrome: From Diagnosis to Long-Term Management-A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Article
- The protective effect and mechanism of dexmedetomidine in inhibiting ferroptosis.Frontiers in pharmacology · 2025Review
- Dexmedetomidine as a Short-Use Analgesia for the Immature Nervous System.International journal of molecular sciences · 2024Article
- Effect of dexmedetomidine on pulmonary function in obese patients undergoing laparoscopic surgery.Perioperative medicine (London, England) · 2024Article
- Predictors for Dexmedetomidine Requirement for Sedation under Regional Anesthesia.Journal of clinical medicine · 2024Article
- BIS-guided sedation prevents the cough reaction of patients under general anaesthesia caused by extubation: a randomized controlled trial.Journal of anesthesia, analgesia and critical care · 2023Article
- Dexmedetomidine-induced hemodynamic instability in patients undergoing orthopedic upper limb surgery under brachial plexus block: a retrospective study.BMC anesthesiology · 2021Article
- Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium.Critical care (London, England) · 2020Review
- Prescribing Patterns of Continuous Infusions in Nonobese versus Obese Children Admitted to the Pediatric Intensive Care Unit.Journal of pediatric intensive care · 2019Article
- Perioperative Pain Management in Morbid Obesity.Drugs · 2019Review
- Dexmedetomidine as an adjuvant during general anesthesia.Journal of anesthesia · 2018Article
- What's New in Critical Illness and Injury Science? Weighing the evidence for dexmedetomidine dosing in critically ill patients with obesity.International journal of critical illness and injury scienceArticle
- A Response Surface Analysis of the Combination of Dexmedetomidine and Sufentanil for Attenuating the Haemodynamic Response to Endotracheal Intubation.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundThis study was designed to investigate the pharmacokinetics and pharmacodynamics of dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery.
methodsMorbidly obese (body mass index ≥40 kg/m
resultsPeak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively). Although clearance was also higher in obese patients than in normal body weight patients (58.6 ± 10.7 vs. 44.9 ± 9.0 l/h, P = 0.02), it was lower in obese patients than in normal body weight patients after normalization to total body weight (0.47 ± 0.07 vs. 0.64 ± 0.09 l/h/kg, P < 0.001). There were no differences in systolic or diastolic blood pressure or heart rate between the two groups within the 30 min. Sedation level was deeper and SpO
conclusionThe pharmacokinetics and pharmacodynamics of dexmedetomidine are significantly different in morbidly obese patients compared with normal weight patients. Level of sedation was significantly deeper, and oxygen saturation was significantly lower, in morbidly obese than in normal weight patients, probably resulting from higher plasma concentration after infusion of 1.0 µg/kg. CLINICAL TRIAL NUMBER, REGISTRY URL: ClinicalTrials.gov (NCT01864187), https://register.clinicaltrials.gov/prs/app/action/LoginUser?ts=1&cx=-jg9qo4 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.